Agile Therapeutics Inc. Stock
Your prediction
Agile Therapeutics Inc. Stock
Our community identified positive and negative aspects for Agile Therapeutics Inc. stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Agile Therapeutics Inc. stock. On the other hand our users think that "Innovation" could be a problem in the future.
Pros and Cons of Agile Therapeutics Inc. in the next few years
Pros
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Agile Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Agile Therapeutics Inc. | - | - | - | - | - | - | - |
| Ardelyx Inc. | 0.640% | 2.840% | 4.881% | 6.187% | 6.465% | 184.469% | -6.409% |
| Krystal Biotech | -2.300% | 3.678% | 18.962% | 33.718% | 37.057% | 193.803% | - |
| Evolus Inc | 1.750% | -1.724% | -7.317% | -46.729% | -45.714% | -13.636% | 73.622% |
Comments
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat
Agile Therapeutics, Inc. (NASDAQ: AGRX) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Show more
Ratings data for AGRX provided by MarketBeat